Syntis Bio is a clinical-stage biopharmaceutical company developing oral therapies that harness the small intestine’s unique biology to provide accessible, effective and sustainable solutions across the healthcare spectrum, from rare genetic disorders to the world’s most prevalent conditions. Syntis is rapidly advancing a pipeline of oral therapies engineered for optimization in the small intestine, the body’s nexus for metabolic control, digestion and drug absorption. The company’s lead program, SYNT-101, is a once-daily oral pill for the treatment of obesity that mimics the effects of gastric bypass surgery. SYNT-101 leverages the power of SYNT™ (SYNthetic Tissue-lining), an oral technology developed by Syntis founders that delivers a safe, transient polymer coating to the duodenum that controls nutrient uptake, as well as enhances both gut-restricted enzyme efficacy and systemic drug absorption for up to 24 hours. Syntis is headquartered in Boston.
Company Details
- Employees
- 17
- Address
- 135 Morrissey Blvd, Boston,massachusetts 02125,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://syntis.bio
- HQ
- Boston, Massachusetts
Syntis Bio Questions
Syntis Bio's website is https://syntis.bio
Syntis Bio's LinkedIn profile is https://www.linkedin.com/company/syntis-bio
Syntis Bio has
17 employees.
View email and phone details for 17
employees at Syntis Bio.
Syntis Bio's industry is
Biotechnology Research
Syntis Bio's top competitors are
Lyra Therapeutics,
Emerald Ai,
Blastid, Inc,
Sherlock Biosciences,
Suono Bio,
Teal Bio,
Beam Therapeutics,
2 Minute Medicine®,
Vivtex,
Lyndra Therapeutics.
Syntis Bio's categories are Biotechnology Research
